Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Presumed non-addictive based on its similarity to LSD. Anecdotal evidence suggests the desire to use it may actually decrease with repeated use.
No evidence of physical dependence. As with LSD, physical dependence is not expected to develop.
The LD50 is unknown. The exact toxic dose has not been established as this is a research chemical with very little history of human usage and no formal toxicological studies have been conducted.
May act as a potential trigger for psychosis in those with underlying psychiatric conditions. Those with a personal or family history of mental illness are advised not to use this substance outside of supervised medical settings. Adverse psychological reactions including delusions and panic attacks become more likely at higher doses.
Seizures are rare but have been reported. Risk is thought to be primarily in those genetically predisposed to seizures, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment.
1cP-AL-LAD is a novel lysergamide that emerged as part of the designer drug market in the early 2020s. The compound is believed to have been first synthesized around 2020 or 2021, reportedly by chemists who were also developing other novel lysergamides during the same period, including compounds…
Not explicitly scheduled but may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) as a structural analogue of LSD. Legal status depends on prosecution interpretation.
Regulated as a defined derivative of lysergic acid under Verzeichnis E point 263 of the Swiss narcotics legislation. An exemption exists for legitimate scientific or industrial purposes.
Became a controlled substance in July 2021. Possession, production, and distribution are prohibited under amended narcotics legislation.
Not specifically scheduled under the Controlled Substances Act. However, as a structural analogue of LSD, it may be prosecuted under the Federal Analogue Act when sold or possessed with intent for human consumption.
15 sources cited
